- In February 2024, AbbVie (U.S.) completed its acquisition of ImmunoGen (U.S.), valued at USD 10.1 billion. The acquisition focuses on enhancing AbbVie’s oncology portfolio, particularly in antibody-drug conjugates, with ImmunoGen’s Elahere for treating platinum-resistant ovarian cancer. This development strengthens AbbVie’s position in the oncology market by adding a new targeted cancer therapy. The acquisition is expected to drive long-term revenue growth despite short-term financial impacts due to acquisition expenses
- In October 2023, Roche (Switzerland) entered into a definitive agreement to acquire Telavant Holdings (U.S.) for USD 7.1 billion. The acquisition grants Roche exclusive rights to develop and commercialize RVT-3101, a promising antibody in Phase 2 trials for inflammatory bowel diseases. This move strengthens Roche's portfolio in autoimmune treatments and accelerates its ability to bring innovative therapies to market. The deal also includes an option to collaborate with Pfizer on a next-generation bispecific antibody
